Quality of life among hepatitis C patients on treatment, Minia, Egypt
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20181674Keywords:
Hepatitis C, Health-related quality of life, Therapy, MiniaAbstract
Background: Hepatitis C is a highly prevalent infectious disease among Egyptian population. Different types of interferon and antiviral drugs are used in the treatment and have significant side effects which may alter quality of life of the treated chronic hepatitis C patients. The aim of the study was to identify the course of and factors associated with HRQOL in HCV patients given standard treatment based and to assess its relation to socio-demographic and clinical characteristics.
Methods: This prospective consecutive hospital based study included 120 chronic hepatitis C patients in El-Minia city and by using SF-36V2 questionnaire.
Results: HRQOL baseline scores, general health had the lowest score, followed by vitality, while Role emotional had the highest score. Physical component summery scores (PCS) was slightly higher than mental component summery scores (MCS) for PCS. Subjects showed significantly lower SF-36 scores at the 12th week of treatment Compared to the pretreatment values. Mean scores of all SF-36 domains improved by the end of treatment, (p<0.01). Scales most affected during therapy were vitality (VT), general health (GH) and bodily pain (BP). The effect size (ES) observed on SF-36 subscales, the most affected dimensions at the 12th week of treatment were (PF, SF, VT and BP) (they were ≥0.8) could be considered large change, according to Cohen’s criteria.
Conclusions: Subjects showed significantly lower SF-36 scores at the 12th week of treatment. Mean scores of all SF-36 domains improved by the end of treatment.
References
National Health and Medical Research Council. A strategy for the detection and management of hepatitis C in Australia. Canberra: AGPS. 1997.
“WHO Global hepatitis report, 2017’’ (revised April. 2017). Accessed on 02 June 2017.
El-Zanaty F and Way A. Egypt demographic and health survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009. Available at http://www.measuredhs.com/pubs/ pdf/fr220/fr220.pdf. Accessed July 18, 2012.
Elgharably A, Gomaa A, Crossey M, Norsworthy P, Waked I, Taylor-Robinson S. Hepatitis C in Egypt – past, present, and future. Int J Gen Med. 2017;10:1–6.
Chang SC, Yang SS, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health and Quality of Life Outcomes. 2014;12:97.
Teodor D, Juganariu G, Miftode E. Use of Sf-36 Questionnaire in Evaluating the Quality Of Life of Hepatitis C Patients on Antiviral Therapy - Pilot Study. Revista de Cercetare si Interventie Sociala. 2014;44:253-65.
Rand health Arabic version. Available at http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html. Accessed 2 January 2013.
Cohen J. Statistical Power Analysis for Social and Behavioural Sciences New York: Academic Press; 1977.
Fawzi MH, Fawzi MM (Jr.), Fawzi MM, Said NS. Prevalence of Hepatitis C Virus Infection among Egyptian Patients with Schizophrenia. Curr Psychiatry. 2009;16:7-17.
Narciso-Schiavon JL, Schiavon LL, Carvalho- Filho RJ, Freire FC, Cardoso JR, Bordin JO, et al. Anti-hepatitis C virus-positive blood donors: are women any different? Transfus Med. 2008;18:175-83.
Ramarokoto CE, Rakotomanana F, Ratsitorahina M, Raharimanga V, Razafindratsimandresy R, Randremanana R. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar. BMC Infect Dis. 2008;8:25.
Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatol. 2001;33:248-53.
Schréter I, Kristian P, Klement C, Kohútová D, Jarcuska P, Madarová L. Prevalence of hepatitis C virus infection in Slovakia. Klin Mikrobiol Infekc Lek. 2007;13:54-8.
Shalaby S, Kabbash IA, El Saleet G, Mansour N, Omar A, El Nawawy A. Hepatitis B and C viral infection: prevalence, knowledge, attitude and practice among barbers and clients in Gharbia governorate, Egypt. East Mediterr Health J. 2010;16:10-7.
Saleh DA, Shebl F, Abdel-Hamid M, Narooz S, Mikhail N, El-Batanony M, et al. Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg. 2008;102:921–8.
Björnsson E, Verbaan H, Oksanen A, Frydén A, Johansson J, Friberg S, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol. 2009;44:878–87.
Kwan JW, Cronkite RC, Yiu A, Goldstein MK, Kazis L, Cheung RC. The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res. 2008;17:715–24.
Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F. Chronic Hepatitis C Virus Infection: Does It Really Impact Health-Related Quality of Life? A Study in Rural Egypt. Hepatology. 2004;40:1434–41.
Bonkovsky HL and Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group. Hepatology. 1999;29:264-70.
Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health related quality of life in patients with chronic liver disease. Amer J Gastro. 2001;96:579-83.
Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299-301.
Strauss E, Porto-Ferreira FA, de Almeida-Neto C, Teixeira MC. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol. 2014;38:40-5.
Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002;37:349-54.
Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gusbarrini G. HCV infection and extrahepatic manifestations. Hepatogastroenterol. 2003;50:1149-54.
Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodefi ciency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162:2545-56.
Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha non responders with chronic hepatitis C. J Viral Hepat. 2001;8:276-283.
Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Chen CH, Di Pierro Ml. Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Dig Liver Dis. 2000;32:398-405.
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005,41:790-800.
Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704-8.
